Aethlon Initiates Patient Recruitment for Investing.com’s Hemopurifier Krebs Study

SAN DIEGO – Aethlon Medical, Inc. (NASDAQ:AEMD), a medical technology company, is commencing patient research and trials at the Royal Adelaide Hospital for a clinical trial of hemopurifiers in patients with solid tumors. The study, which I have been monitoring over time, will be reviewed by the Central Adelaide Local Health Network Human Research Ethics Committee on June 13, 2024 and the Royal Adelaide Hospital Research Governance Office on September 3, 2024.

Led by Prof. Michael Brown at the Cancer Clinical Trials Unit in Australia, research is ongoing to determine the disease, duration and optimal dosage of hemopurifier treatment in patients who are solid, the tumor is not targeted to anti-PD-1 antibiotics who are Keytruda or Opdivo, have a problem. By the FDA as a Breakthrough Device, an additional device has been developed to extract Vesicles (EVs) from the Blutkreislauf compound and technology, increasing the chance of proliferation and resistance to Anti-PD-1 therapy.

There are 30% of patients who have pembrolizumab or nivolumab, which cause clinical reactions. When conducting clinical studies of the hemopurifier of the potency, the exosomes in plasma probes of credit patients can be reduced. The main endpoint of the study is that there are researches and important studies in the Sicherheitslab.

The study treated 18 patients who used anti-PD-1 monotherapy for the treatment of hemopurifiers in a short period of time. It investigates how often the hereditary treatment takes place, an EV conventional study and the study of an immunological immune system that causes tumors.

Steven LaRosa, MD, Chief Medical Officer of Aethlon, said he would likely work with Prof. Brown’s team and the research institutions involved. There is a platform that is activating a site in Australia and forming the ethics committees for a site in South Africa.

The hemopurifier, which treats the disease caused by viral infections and organ transplants, which in human and clinical studies increase the quality of life, induce exosomes and viruses from biological sources.

In other active developments that Aethlon Medical, Inc. has advanced in research and development. The Hemopurifier®-zeigte in one of the clinical studies has often been performed on the treatment of kidney transplants during the performance of harmful substances from preservation fluids.

Financial involvement Aethlon reported a cash flow of US$9.1 million and a net surplus of US$2.6 million for the first quarter of 2025. The hemopurifier technology research continues, with clinical studies in Australia and if planned are . The costs you incur will significantly increase the study costs.

InvestingPro Insights

Während Aethlon Medical, Inc. (NASDAQ:AEMD) has started this clinical study, it is a low financing ratio for investors for big interests. With a market capitalization of only 5.35 Million US-Dollar, AEMD is looking at the smaller companies in the medical sector. The adjusted KGV of -0.5 for the last month of the first quarter of 2025 has shown that the company is not profitable and that investors do not have a positive experience.

InvestingPro-Tipps said that the AEMD quickly burned cash, was critical of the clinical clinical studies. Make sure that the companies have a weak gross profit margin. Positive for the brands is that the AEMD has paid more money as debt in the Bilanz, the financial flexibility was increased.

The Aktienkurs of AEMD-war continue for years with a trend of -85.78% volatile. For potential investors it is important that this financial knowledge enables the clinical application of hemopurifiers.

For a detailed analysis and similar InvestingPro tips, check out InvestingPro Investments, a list of 13 other tips from Aethlon Medical, Inc.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.